 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...184185186187188189190191192193194...208209» |
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: INPHASE: A Phase ? Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer (clinicaltrials.gov) - Sep 18, 2019
P2, N=60, Recruiting, Sponsor: Jinming Yu
- | AiTan (rivoceranib) / LSK BioPartners
Retrospective data, Journal, Real-World Evidence: Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting. (Pubmed Central) - Sep 18, 2019
The most common adverse events apatinib-related included hypertension (19.2%), hand-foot syndrome (11.5%), and mucous membrane reaction (17.3%). And treatment-related grade 3/4 toxicities were low.Apatinib showed favorable efficacy and safety and could be a treatment option in patients with advanced NSCLC experiencing progression after second-line and more treatment.
- | AiTan (rivoceranib) / HLB Bio Group
Trial completion date, Metastases: ANGEL: A Study to Evaluate Rivoceranib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Participants With Gastric Cancer (clinicaltrials.gov) - Sep 18, 2019
P3, N=460, Active, not recruiting, Sponsor: LSK BioPartners Inc.
And treatment-related grade 3/4 toxicities were low.Apatinib showed favorable efficacy and safety and could be a treatment option in patients with advanced NSCLC experiencing progression after second-line and more treatment. Trial completion date: Mar 2019 --> Mar 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) - Sep 17, 2019
P2, N=58, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial completion date: Mar 2019 --> Mar 2020 Trial primary completion date: Jun 2019 --> Sep 2019
- AiTan (rivoceranib) / HLB Bio Group, camrelizumab (INCSHR1210) / Incyte
Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_843;
Funding: Has not received any funding. Clinical trial identification: ChiCTR1800019329 (Chinese Clinical Tiral Registry).
- AiTan (rivoceranib) / HLB Bio Group
A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC) (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_814;
P2
However, patients with uncontrolled primary tumor or trachea/bronchi eroded should been cautiously considered to use.Legal entity responsible for the study: Fudan University Shanghai Cancer Center. Funding: Jiangsu Hengrui Medicine.
- AiTan (rivoceranib) / HLB Bio Group, camrelizumab (INCSHR1210) / Incyte
A multicenter, randomized, controlled, phase II trial exploring adjuvant combined therapy of apatinib and SHR-1210 (anti-PD-1), in patients with hepatocellular carcinoma at high risk of recurrence after radical resection (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_686;
P1/2
Funding: Has not received any funding. Clinical trial identification: NCT 03839550.
- AiTan (rivoceranib) / HLB Bio Group
Efficacy and safety of apatinib in heavily pretreated metastatic adenocarcinoma of the head and neck (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_656;
P2
Apatinib can be considered as a treatment option for adenocarcinoma of the head and neck with metastatic diseases.Legal entity responsible for the study: CAMS & PUMC, National Cancer Center, Cancer Hospital. Funding: Has not received any funding.
- SHR6390 / Jiangsu Hengrui Medicine, pyrotinib (HTI-1001) / Jiangsu Hengrui Medicine
Significant benefit of pyrotinib combined with SHR6390 in patients with multiline-resistant HER2-positive advanced gastric cancer (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_504;
P1
The optimal drug doses and tolerability of this combination treatment will be explored in future studies.Legal entity responsible for the study: Zuhua Chen. Funding: The National Key Research and Development Program of China (No.
- AiTan (rivoceranib) / HLB Bio Group
VEGFR2 and ITGA polymorphisms as novel predictors of therapeutic response and toxicities for pediatric and young adult sarcoma undergoing anti-angiogenic therapy (Room 311) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_262;
VEGFR2 (rs2071559) as well as ITGA (rs1126643) might serve as pan-sarcoma biomarkers for VEGFR2 targeted therapy and warrant further validation for its biological and clinical implications.Legal entity responsible for the study: Ruijin Hospital. Funding: Has not received any funding.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
New P2 trial: ASGARD: Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens (clinicaltrials.gov) - Sep 12, 2019
P2, N=40, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- | AiTan (rivoceranib) / LSK BioPartners
Preclinical, Journal: Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice. (Pubmed Central) - Sep 12, 2019
In conclusion, Apa may improve the effective perfusion of tumor vessels and increase the intratumoral distribution of ADR in a certain time window via normalizing tumor vessels. This normalization window (7 to 10 days of treatment) may contribute to develop a regimen of combined medication in clinic use of Apa.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
New P2 trial: Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer (clinicaltrials.gov) - Sep 11, 2019
P2, N=77, Not yet recruiting, Sponsor: Fuzhou General Hospital
- | AiTan (rivoceranib) / Elevar Therapeutics
Biomarker, Enrollment open: BIOVAS: BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Sep 11, 2019
P2, N=30, Recruiting, Sponsor: Ruijin Hospital
This normalization window (7 to 10 days of treatment) may contribute to develop a regimen of combined medication in clinic use of Apa. Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / LSK BioPartners
Assessment quality of life with hand-foot syndrome induced by apatinib combined with anti-PD-1 therapy in NSCLC (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_4285;
HFS-14 may serve as a more sensitive and valuable tool for early measuring HFS-related QoL impairment. Legal entity responsible for the study: The authors.
- AiTan (rivoceranib) / LSK BioPartners
Randomized phase III ANGEL study of rivoceranib (apatinib) + best supportive care (BSC) vs placebo + BSC in patients with advanced/metastatic gastric cancer who failed ≥2 prior chemotherapy regimens (Madrid Auditorium (Hall 2)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_3525;
P3
Clinical trial identification: NCT03042611. Legal entity responsible for the study: LSK BioPharma.
- AiTan (rivoceranib) / LSK BioPartners
Apatinib in treating patients with platinum-resistant or platinum-refractory recurrent or metastatic nasopharyngeal carcinoma (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2870;
P2
More attention needs to be paid to toxicity management. Legal entity responsible for the study: Jiangsu Hengrui Pharmaceutical Co., Ltd.
- AiTan (rivoceranib) / LSK BioPartners, paclitaxel / Generic Mfg.
Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2455;
P1
Clinical trial identification: NCT03244774; Release date: August 10, 2017. Legal entity responsible for the study: Rongbo Lin.
- AiTan (rivoceranib) / LSK BioPartners, paclitaxel / Generic Mfg.
Apatinib in combination with docetaxol and S1 chemotherapy in the first-line treatment of metastatic gastric cancer (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2449;
This modality also exhibits promising efficacy,which might provide a new therapeutic strategy for metastatic gastric cancer. Legal entity responsible for the study: The authors.
- AiTan (rivoceranib) / LSK BioPartners
Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2448;
P=N/A
Antiangiogenic therapy may be a good strategy for the treatment of AFPGC. Clinical trial identification: AHEAD-G202 (NCT02668380).
- AiTan (rivoceranib) / LSK BioPartners
Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: A prospective clinical study (data updated) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2434;
Moreover, the toxicities were tolerable and could be clinically managed. Legal entity responsible for the study: The authors.
- fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2129;
P1, P2
And this is the first report of a PARP inhibitor in Chinese patients with BRCA1/2 mutations and recurrent ovarian cancer. Clinical trial identification: NCT03509636.
- fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2084;
P2
FLU demonstrated single-agent antitumour activity in BC and OC, particularly in platinum-sensitive and BRCA Mut OC. Clinical trial identification: NCT03509636.
- AiTan (rivoceranib) / LSK BioPartners
Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): A multi-center phase II randomized clinical trial (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1930;
P2
Legal entity responsible for the study: An IIT trial by Ruijin Hospital, Orthopaedic oncology group. Funding: Has not received any funding.
- imatinib / Generic Mfg., AiTan (rivoceranib) / LSK BioPartners, Sutent (sunitinib) / Pfizer
Efficacy and safety of apatinib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1898;
Apatinib warrants further investigation in GISTs. Clinical trial identification: ChiCTR1800020407.
- AiTan (rivoceranib) / LSK BioPartners
Efficacy and safety of VEGFR2 inhibitor apatinib combined with chemotherapy for sarcoma in stage IV (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1895;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- AiTan (rivoceranib) / LSK BioPartners
VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult patients (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1893;
VEGFR2 (rs2071559) as well as ITGA (rs1126643) might serve as pan-sarcoma biomarkers for VEGFR2-targeted therapy and warrant further validation for its biological and clinical implications. Legal entity responsible for the study: Ruijin Hospital, Orthopaedic Oncology Group.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Hakko Kirin, Roche, plinabulin (BPI 2358) / BeyondSpring
The effect of increasing doses of pegfilgrastim (Peg) on thrombocytopenia (T) in breast cancer (BC) patients (pts) receiving taxotere (Doc), doxorubicin, cyclophosphamide (TAC) and plinabulin (Plin) (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1813;
P2/3
Clinical trial identification: BPI-2358-106. Legal entity responsible for the study: BeyondSpring Pharmaceuticals, Inc.
- plinabulin (BPI 2358) / BeyondSpring
DUBLIN-3, a stage IIIb/IV NSCLC phase (Ph)3 trial comparing the plinabulin (P)/Docetaxel(D) combination with D Alone (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1732;
P3
Legal entity responsible for the study: BeyondSpring Pharmaceuticals, Inc. Funding: BeyondSpring Pharmaceuticals, Inc.
- AiTan (rivoceranib) / LSK BioPartners
Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1661;
Patient’s quality of life and the compliance with therapy hads been increased by use of oral drugs. We found that in the patients who were treated with erlotinib, or patients with EGFR 21 mutation, or male, their PFS tended to be prolonged compared to other patients.
- AiTan (rivoceranib) / LSK BioPartners, temozolomide / Generic Mfg.
A phase II clinical trial evaluating the efficacy and safety of apatinib combined with dose-dense temozolomide in recurrent glioblastoma (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1556;
P2
Clinical randomized controlled trial is warranted to be designed to confirm the results. Clinical trial identification: NCT03660761.
- | AiTan (rivoceranib) / LSK BioPartners
Journal: Targeting autophagy enhances apatinib-induced apoptosis via endoplasmic reticulum stress for human colorectal cancer. (Pubmed Central) - Sep 11, 2019
Furthermore, the combination of apatinib with autophagy inhibitor chloroquine (CQ) tends to have the most significant anti-tumor effect of CRC both in vitro and in vivo. Overall, our data show that because apatinib treatment could induce ER stress-related apoptosis and protective autophagy in human CRC cell lines, targeting autophagy is a promising therapeutic strategy to relieve apatinib drug resistance in CRC.
- | Elunate (fruquintinib) - Chi / Med
Journal: Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. (Pubmed Central) - Sep 10, 2019
The existing clinical trials and future prospects of fruquintinib in mCRC will be discussed in this article. In addition, to better understand the role of fruquintinib in this setting, recent advances in other anti-VEGFR TKIs for mCRC treatment are also reviewed herein.
- | docetaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: PROACH: Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy (clinicaltrials.gov) - Sep 10, 2019
P2, N=43, Recruiting, Sponsor: Ruijin Hospital
In addition, to better understand the role of fruquintinib in this setting, recent advances in other anti-VEGFR TKIs for mCRC treatment are also reviewed herein. N=188 --> 43
- ||| camrelizumab (INCSHR1210) / Incyte
Tweet @Alfdoc2 CAMRELIZUMAB (Twitter) - Sep 8, 2019
- ||||| camrelizumab (INCSHR1210) / Incyte, AMG 510 / Amgen
Dear Colleagues, The @OncoAlert 🚨Tweet of the day🙌 Our #OncoAlert Highlights⚡️for @IASLC #WCLC19 Sunday 9/8/19📅 AMG510, KN189, MYSTIC & CAMRELIZUMAB Thank you🙏: @CharuAggarwalMD @BrendonStilesMD @StephenVLiu @Alfdoc2 @g_mountzios @Jbauml @s_couraud Sincerely @weoncologists (Twitter) - Sep 8, 2019
- ||||| camrelizumab (INCSHR1210) / Incyte
Camrelizumab, a new player in the field of PD1 inhibitor @IASLC #WCLC19 @Immunopole #OncoAlert would it be available outside China?! (Twitter) - Sep 8, 2019
- ||||| AiTan (rivoceranib) / LSK BioPartners
Clinical: #WCLC2019 APATINIB, an oral VEGF inhibitor shows good activity with DCR of ~83% after failure of first line chemo (before chemo/IO ) promising option for this population (Twitter) - Sep 8, 2019
- |||| plinabulin (BPI 2358) / BeyondSpring
Our poster showing increased QOL with plinabulin and docetaxel for #LCSM at #WCLC2019 (Twitter) - Sep 8, 2019
- | imrecoxib (BAP 909) / Jiangsu Hengrui Medicine, fluconazole / Generic Mfg.
Clinical, PK/PD data, Journal: Effect of Fluconazole on the Pharmacokinetics Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers. (Pubmed Central) - Sep 7, 2019
The ratio (imrecoxib + fluconazole/imrecoxib) for AUC was 1.72 (90% CI, 1.41-2.11) and for Cmax it was 1.88 (90% CI, 1.59-2.21). Hence, it is necessary to adjust the imrecoxib dose when it is concurrently used with other CYP2C9 inhibitors.
- | AiTan (rivoceranib) / LSK BioPartners
Journal, PARP Biomarker, IO Biomarker: Apatinib enhances chemosensitivity of acute myeloid leukemia hl60 cells to cytarabine by inducing apoptosis. (Pubmed Central) - Sep 6, 2019
Hence, it is necessary to adjust the imrecoxib dose when it is concurrently used with other CYP2C9 inhibitors. Apatinib combined with cytarabine resists acute myeloid leukemia through synergistically regulating cell cycle and promoting apoptosis.
- | imrecoxib (BAP 909) / Jiangsu Hengrui Medicine
Clinical, Journal: Simultaneous determination of imrecoxib and its two active metabolites in plasma of hepatic impairment patients by liquid chromatography-tandem mass spectrometry. (Pubmed Central) - Sep 6, 2019
The method validation was carried out in agreement with the FDA guidance. Furthermore, the pharmacokinetic properties of imrecoxib and its two active metabolites were characterized in patients with moderate hepatic impairment, by using the developed and validated method.
- | camrelizumab (INCSHR1210) / Incyte
Clinical, Journal: The clinical reports on adrenal insufficiency of patients with advanced solid tumors accepting anti-PD-1 antibody, SHR-1210 therapy (Pubmed Central) - Sep 5, 2019
The incidence of SHR-1210 related adrenal insufficiency of patients with advanced solid tumors is low, and the symptoms can be effectively ameliorated by hormone replacement therapy. The potential adverse outcome of adrenal insufficiency following immunotherapy should be noticed by clinicians to avoid the occurrence of adrenal crisis.
- | Onglyza (saxagliptin) / AstraZeneca
Journal: Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases. (Pubmed Central) - Aug 30, 2019
When the amide derivatives of gliptins were incubated with DPP-4, they were completely hydrolyzed at a rate far more than that from the parent drug, including saxagliptin-amide. Therefore, it was proposed that gliptins, except saxagliptin, were initially hydrolyzed to their amides by DPPs, which was the rate-limiting step in generating the carboxylic end-product.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P1 trial: MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 29, 2019
P1, N=20, Not yet recruiting, Sponsor: SYZ Cell Therapy Co..
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, Trial primary completion date: A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor (clinicaltrials.gov) - Aug 29, 2019
P1, N=28, Recruiting, Sponsor: SYZ Cell Therapy Co..
Therefore, it was proposed that gliptins, except saxagliptin, were initially hydrolyzed to their amides by DPPs, which was the rate-limiting step in generating the carboxylic end-product. Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2020 --> Jul 2020
- | AiTan (rivoceranib) / HLB Bio Group, Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New P1 trial, Metastases: Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma. (clinicaltrials.gov) - Aug 29, 2019
P1, N=20, Recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Platinum resistant: Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer (clinicaltrials.gov) - Aug 28, 2019
P2, N=28, Not yet recruiting, Sponsor: Peking Union Medical College Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) (clinicaltrials.gov) - Aug 28, 2019
P2, N=21, Not yet recruiting, Sponsor: Beijing Sanbo Brain Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=62, Not yet recruiting, Sponsor: Zhongshan Hospital Xiamen University